Zevra Therapeutics (ZVRA) Q3 2026 Earnings

Yes. Zevra Therapeutics reported Q3 2026 earnings of $0.26 a share on Nov 3, 2026, beating the $0.18 consensus estimate by 47.1%. Revenue was $37.8M against a $37.4M estimate.

Zevra Therapeutics posted a strong third quarter of fiscal 2026, beating Wall Street on both the top and bottom lines and extending its consensus EPS beat streak to four consecutive quarters. The Niemann-Pick disease company reported GAAP earnings per share of $0.26, clearing the $0.18 consensus estimate by 47.14%; that figure includes $5.10 million in noncash income from fair value adjustments to warrant and contingent value rights liabilities, compared with $5.50 million of noncash expense in the year-ago period. Revenue of $37.76 million edged past the $37.41 million consensus by 0.91% and climbed 44.9% year over year, powered primarily by $34.00 million in net revenue from MIPLYFFA, its approved NPC therapy. The commercial momentum reflects steady prescription growth in the U.S., where total enrollment forms since launch have reached 197, while real-world data presented at a recent scientific symposium continued to demonstrate durable disease stabilization. Looking ahead, Zevra plans to file a supplemental NDA for MIPLYFFA in infants under 24 months in Q1 2027 and is awaiting the outcome of its EU marketing authorisation re-examination, with a $270.90 million cash position backing those efforts.